MetLife (MET) Stock Forecast & Price Target

$78.99 +1.78 (+2.31%)

Closing price 05/27/2025 03:59 PM Eastern

Extended Trading

$79.06 +0.07 (+0.09%)

As of 05/27/2025 07:36 PM Eastern

MetLife - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
0

Hold
1

Buy
12

Based on 13 Wall Street analysts who have issued ratings for MetLife in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a hold rating, and 12 have given a buy rating for MET.

Consensus Price Target

$94.17
19.21% Upside

According to the 13 analysts' twelve-month price targets for MetLife, the average price target is $94.17. The highest price target for MET is $99.00, while the lowest price target for MET is $86.00. The average price target represents a forecasted upside of 19.21% from the current price of $78.99.

Get the Latest News and Ratings for MET and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MetLife and its competitors.

MET Analyst Ratings Over Time

Type	Current Forecast 5/28/24 to 5/28/25	1 Month Ago 4/28/24 to 4/28/25	3 Months Ago 2/28/24 to 2/27/25	1 Year Ago 5/29/23 to 5/28/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	13 Buy rating(s)	11 Buy rating(s)	12 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$94.17	$92.46	$92.58	$79.08
Forecasted Upside	19.21% Upside	21.74% Upside	10.12% Upside	11.41% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

MET Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MET Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

MetLife Stock vs. The Competition

Type	MetLife	Finance Companies	S&P 500
Consensus Rating Score	2.92	2.53	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	19.21% Upside	27.80% Upside	14.19% Upside
News Sentiment Rating	Positive News See Recent MET News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/19/2025	Morgan Stanley 3 of 5 stars	Nigel Dally Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$94.00 ➝ $99.00	+22.51%
5/6/2025	Wells Fargo & Company 3 of 5 stars	Elyse Greenspan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$91.00 ➝ $94.00	+21.46%
4/11/2025	Barclays 3 of 5 stars	Alex Scott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$95.00 ➝ $88.00	+23.51%
4/9/2025	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ryan Krueger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$98.00 ➝ $95.00	+40.70%
4/2/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian Meredith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$94.00 ➝ $98.00	+19.58%
4/2/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	John Barnidge Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$92.00 ➝ $94.00	+14.87%
4/2/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jimmy Bhullar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$88.00 ➝ $86.00	+5.94%
3/7/2025	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
1/23/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jack Matten Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$97.00	+13.09%
11/27/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Kligerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$97.00 ➝ $99.00	+11.50%
Get the Latest News and Ratings for MET and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for MetLife and its competitors with MarketBeat's FREE daily newsletter.
9/27/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$89.00 ➝ $95.00	+14.71%
8/1/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$99.00 ➝ $96.00	+24.92%
7/23/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$83.00 ➝ $89.00	+18.26%
5/22/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$77.00 ➝ $80.00	+9.50%
1/8/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$70.00 ➝ $80.00	+16.08%
10/4/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$71.00	+18.33%
8/4/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$70.00 ➝ $74.00	+14.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:46 AM ET.

Should I Buy MetLife Stock? MET Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, May 25, 2025. Please send any questions or comments about these MetLife pros and cons to contact@marketbeat.com.

MetLife
Bull Case

Here are some ways that investors could benefit from investing in MetLife, Inc.:

The current stock price is around $89, which is close to its 1-year high, indicating strong market performance and investor confidence.
MetLife, Inc. recently reported a significant revenue increase of 15.6% year-over-year, showcasing robust growth in its financial performance.
The company has initiated a $3.00 billion share repurchase program, suggesting that the board believes the stock is undervalued, which can enhance shareholder value.
MetLife, Inc. has increased its quarterly dividend to $0.5675 per share, reflecting a commitment to returning value to shareholders and a healthy payout ratio of 36.91%.
Analysts have a consensus rating of "Moderate Buy" for MetLife, Inc., with a target price around $94, indicating potential for future price appreciation.

MetLife
Bear Case

Investors should be bearish about investing in MetLife, Inc. for these reasons:

The company reported an EPS of $1.96, which missed analysts' expectations of $2.00, raising concerns about its ability to meet future earnings targets.
Despite revenue growth, the net margin of 6.19% may indicate challenges in cost management and profitability compared to industry standards.
MetLife, Inc. has a price-to-earnings ratio of 12.93, which, while not excessively high, may suggest limited growth potential compared to higher-growth companies.
Some analysts have lowered their price targets for MetLife, Inc., indicating a cautious outlook on the stock's short-term performance.
The stock has a beta of 0.85, suggesting it is less volatile than the market, which may limit potential gains during bullish market conditions.

MET Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for MetLife is $94.17, with a high forecast of $99.00 and a low forecast of $86.00.
: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MetLife in the last year. There is currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MET shares.
: According to analysts, MetLife's stock has a predicted upside of 19.21% based on their 12-month stock forecasts.
: MetLife has been rated by research analysts at Barclays, Cowen, JPMorgan Chase & Co., Keefe, Bruyette & Woods, Morgan Stanley, Piper Sandler, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like MetLife more than other "finance" companies. The consensus rating score for MetLife is 2.92 while the average consensus rating score for "finance" companies is 2.53. Learn more on how MET compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:MET) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MetLife (MET) Stock Forecast & Price Target